Abstract
Objective S-Adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are indicators of global transmethylation and may play an important role as markers of severity of COVID-19.
Methods The levels of plasma SAM and SAH were determined in patients admitted with COVID-19 (n = 56, mean age = 61). Lung injury was identified by computed tomography (CT) in accordance with the CT0-4 classification.
Results SAM was found to be a potential marker of lung damage risk in COVID-19 patients (SAM > 80 nM; CT3,4 vs. CT 0-2: relative ratio (RR) was 3.0; p = 0.0029). SAM/SAH > 6.0 was also found to be a marker of lung injury (CT2-4 vs. CT0,1: RR = 3.47, p = 0.0004). Interleukin-6 (IL-6) levels were associated with SAM (ρ = 0.44, p = 0.01) and SAH (ρ = 0.534, p = 0.001) levels.
Conclusions High SAM levels and high methylation index are associated with the risk of lung injury in COVID-19 patients. The association of SAM and SAH with IL-6 indicates an important role of transmethylation in the development of cytokine imbalance in COVID-19 cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Russian Foundation for Basic Research (RFBR), project № 20-04-60251\20.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study included 56 COVID-19 patients who were admitted in the pulmonary department of the Burdenko Main Military Clinical Hospital from September 2020 to December 2020. Approval for this study was given from the ethics committee of Burdenko Main Military Clinical Hospital. Informed written consent was obtained from each patient. The reporting of this study conforms to STROBE guidelines.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The anonymized data used to support the findings of this study are available from the corresponding author upon request.
https://figshare.com/articles/dataset/SAM_SAH_Covid_patients_data_xls/16539591
Abbreviations
- 2’-OMTase
- 2’-O-methyltransferase
- Ado
- adenosine
- ALT
- alanine aminotransferase
- AST
- aspartate aminotransferase
- CRB
- C-reactive protein
- COVID-19
- coronavirus disease 2019
- CT
- computed tomography
- ED
- endothelial dysfunction
- ESR
- the erythrocyte sedimentation rate
- GSH
- glutathione
- HCT
- hematocrit
- Hcy
- homocysteine
- HGB
- hemoglobin
- IL-6
- interleukin-6
- LI
- leukocyte index
- LPS
- lipopolysaccharide
- MAPK
- mitogen-activated protein kinases
- MCH
- mean erythrocyte hemoglobin
- MCHC
- mean corpuscular hemoglobin concentration
- MCV
- mean erythrocyte volume
- N7-Mtase
- (guanine-N7)-methyltransferase
- Nsp
- nonstructural proteins
- OR
- odds ratio
- PLT
- platelets
- RBC
- red blood cells
- RR
- relative risk
- SAH
- S-adenosylhomocysteine
- SAHH
- SAH hydrolase
- SAM
- S-adenosylmethionine
- SARS-CoV-2
- acute respiratory syndrome coronavirus-2
- WBC
- white blood cells
